NEW DATA SHOWCASES HOW AMGEN IS ADVANCING ALL ANGLES OF CANCER CARE THROUGH INNOVATIVE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2022

/PRNewswire/ -- Amgen (NASDAQ: AMGN) will present new data from across its broad oncology innovative medicines and biosimilars portfolio and robust pipeline at...

Related Keywords

Japan ,Qatar ,Malaysia ,Australia ,Taiwan ,United States ,Hong Kong ,United Kingdom ,Argentina ,Brazil ,Colombia ,United Arab Emirates ,Canada ,Mexico ,Puerto Rico ,Thailand ,Israel ,Kuwait ,Singapore ,Saudi Arabia ,South Korea ,Panama ,Switzerland ,Chicago ,Illinois ,Turkey ,Great Britain ,American ,Megan Fox ,Jessica Akopyan ,Stevens Johnson ,Spira Al ,Davidm Reese ,Kyowa Kirin Co Ltd ,Amgen ,American Society Of Clinical Oncology ,Drug Administration ,Beigene Ltd ,Takeda Pharmaceutical Company ,Exchange Commission ,Therapeutics Inc ,European Union ,Amgen Inc ,Teneobio Inc ,American Cancer Society ,Results From ,Ahead Trial ,Versus Bevacizumab ,Type Metastatic Colorectal ,Acquired Resistance ,American Society ,Clinical Oncology ,Annual Meeting ,Amgen Oncology ,Presentation Times ,Oral Presentation Session ,Clinical Science Symposium ,New Era ,Plenary Series ,Rapid Abstract Updates ,Presentation Session ,Lung Cancer ,Non Small Cell Metastatic ,Poster Discussion Session ,Skin Cancers ,Poster Presentation Session ,Lung Cancer Non Small ,Poster Session ,Genitourinary Cancer ,Developmental Therapeutics ,Molecularly Targeted Agents ,Tumor Biology ,Poster Presentation ,Gastrointestinal Cancer ,Plenary Session ,Primary Track ,Special Sessions ,Oral Presentation ,Breast Cancer ,Sponsored Studies ,Hematologic Malignancies ,Plasma Cell Dyscrasia ,Oral Abstract Session ,Risk Reduction ,Hereditary Cancer ,Through Project Orbis ,Marketing Authorization Applications ,Non Small Cell Lung Cancer ,Lung Disease ,Dow Jones Industrial Average ,Best Workplaces ,Great Place ,Five Prime Therapeutics ,Advancing Oncology ,Lung Cancer Survival ,